Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on

Weight loss requires patience. Americans spend millions on diets, surgical procedures, medications, and fitness programs, but healthcare providers say there’s no quick fix for obesity. Someone with a body mass index of 30+ is considered to have obesity. 57 medical conditions, including type 2 diabetes, heart disease, osteoarthritis, and sleep apnea, are linked to the condition — but it takes more than just diet and exercise to help control it.

Finding the appropriate, qualified healthcare provider who understands the disease is crucial. They can help the person with obesity develop a tailored plan. Dr. Deborah Horn, Medical Director of the Center for Obesity Medicine and Metabolic Performance at The University of Texas Health Science Center at Houston Medical School, explains the science behind weight loss, how our metabolism and hormones play a role and the solutions, including lifestyle changes, prescription medicines, and surgery available for people with obesity.

Plus, hear Lisa Singleton’s story, a Novo Nordisk patient ambassador. Novo Nordisk is committed to changing obesity by working to improve the lives of people with obesity and collaborating broadly to change how the world sees, prevents, and treats obesity.

Sponsored by: Novo Nordisk / Obesity Market Development

Health, Wealth, Beauty, and Business

Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]

iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.

There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.